Warsaw, Poland – Eva L. Feldman, MD, PhD, was a featured speaker at the “International Scientific Conference on Stem Cells: Research and Treatment,” held Dec. 8-9, 2017.
Dr. Feldman’s talk, “Stem Cell Therapy in ALS: Where Are We Today” highlighted the research effort of Dr. Feldman and the Program for Neurology Research & Discovery to use stem cells in the treatment of amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease.
Dr. Feldman is the Principal Investigator of the first human clinical trial of intraspinal transplantation of stem cells in patients with ALS, which has completed Phase I and Phase II trials, and included 30 patients.
Those studies showed that intraspinal transplantation of up to 16 million stem cells in patients with ALS was safe and well-tolerated, and caused no acceleration in disease progression, according to data recently published in the journal Neurology. Additionally, 70 percent of patients recovered to higher levels than those of the historic control.
Preparations are under way for Phase 2b, which will expand this procedure to 60 new stem-cell recipients.